Artificial blood for therapeutic and laboratory usage: Where do we stand?
- PMID: 39345268
- PMCID: PMC11427025
- DOI: 10.1063/5.0186931
Artificial blood for therapeutic and laboratory usage: Where do we stand?
Abstract
The scarcity of blood for transfusion purposes has been widely acknowledged. Surgical therapeutic processes, war zones, and post-disaster treatments demand a huge amount of blood. Modern-day laboratories also require blood for bioengineering experimentation. Therefore, an artificially devised solution capable of mimicking the blood functions from biological and engineering relevance would be a noteworthy discovery of contemporary science. The experience drawn from discarded century-old blood substitutes has led us to technologically more advanced present-day solutions, which are better at carrying out the physiological functions of blood. Aiming at safety, stability, non-toxicity, and compatibility in terms of immuno-response, a remarkable number of substitutes are being tried to mimic the physiological properties and functions of red blood cells, platelets, plasma, and white blood cells. Despite significant efforts and time devoted, for transfusion, no product so far has been able to replace natural blood. This article puts together the important developments in blood substitutes that have evolved over the years, including substitutes for clinical as well as engineering requirements. It also points out the recent endeavors of synthesizing blood cells through modern synthetic routes. It has been highlighted that none of the blood substitutes have achieved the required efficacy so that they can be used in vivo. Finally, the emerging trends and future research needs have been stressed upon.
© 2024 Author(s).
Conflict of interest statement
The authors have no conflicts to disclose.
Similar articles
-
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001230. doi: 10.1002/14651858.CD001230.pub2. Cochrane Database Syst Rev. 2008. PMID: 18646068
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.Cochrane Database Syst Rev. 2001;(3):CD003234. doi: 10.1002/14651858.CD003234. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003234. doi: 10.1002/14651858.CD003234.pub2. PMID: 11687058 Updated.
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948. Health Technol Assess. 2024. PMID: 39367772 Free PMC article.
References
-
- Amberson W. R., “Blood substitutes,” Biol. Rev. 12(1), 48–86 (1937). 10.1111/j.1469-185X.1937.tb01222.x - DOI
-
- Hae W. K. and Greenburg A. G., “Artificial oxygen carriers as red blood cell substitutes: A selected review and current status,” Artif. Organs, 28, 813–828 (2004). - PubMed
-
- Conley C. L. and Schwartz R. S., “Blood,” Encyclopedia Britannica (2023), https://www.britannica.com/science/blood-biochemistry, accessed 15 September 2023.